finance.yahoo.com
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The approval is based on Phase 3 trial data and includes reported longer‑term maintenance results.
Adults with moderately to severely active Crohn's disease, patients who have not responded to or tolerated other biologics or immunomodulators, clinicians who treat IBD, and researchers following IL‑23–targeted therapies.
What To Know
FDA approved Omvoh (mirikizumab-mrkz) for adults with moderately to severely active Crohn's disease, expanding its U.S. indications beyond ulcerative colitis. The approval is based on Phase 3 VIVID-1 results and mentions maintenance data from an open-label extension (VIVID-2).
The press release includes indication and safety information and notes it was a PR Newswire distribution from Eli Lilly. Omvoh is an IL‑23 p19 antagonist already approved for ulcerative colitis and now approved for Crohn's disease in adults.
The company highlights results from the VIVID-1 Phase 3 trial showing clinical remission and endoscopic response rates at one year and continued remission in many patients who stayed on treatment in an open‑label extension. The release also lists important safety warnings and the approved indication language.
Practical points: This is a regulatory/industry press release announcing FDA approval rather than independent clinical reporting. If you or your clinician are considering a new treatment option, discuss eligibility, benefits, risks, and monitoring with your care team. Insurance coverage and step therapy rules may affect access.
The source is a company/PR Newswire press release summarizing the FDA approval and trial results; it is not an independent analysis. Open‑label extension data can have selection bias, and treatment decisions should be based on clinical discussion and full prescribing information.
Coverage, prior authorization, and comparative effectiveness versus other IBD therapies are not addressed here.
